Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Current Liabilities (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Total Current Liabilities for 5 consecutive years, with $30.7 million as the latest value for Q4 2024.

  • On a quarterly basis, Total Current Liabilities rose 8.3% to $30.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $30.7 million, a 8.3% increase, with the full-year FY2024 number at $30.7 million, up 8.3% from a year prior.
  • Total Current Liabilities was $30.7 million for Q4 2024 at Caribou Biosciences, up from $28.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $30.7 million in Q4 2024 to a low of $12.4 million in Q4 2020.
  • A 5-year average of $26.2 million and a median of $27.4 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 108.48% in 2021, then rose 0.62% in 2023.
  • Caribou Biosciences' Total Current Liabilities stood at $12.4 million in 2020, then soared by 108.48% to $25.8 million in 2021, then increased by 8.9% to $28.1 million in 2022, then increased by 0.62% to $28.3 million in 2023, then rose by 8.3% to $30.7 million in 2024.
  • Per Business Quant, the three most recent readings for CRBU's Total Current Liabilities are $30.7 million (Q4 2024), $28.3 million (Q4 2023), and $28.1 million (Q4 2022).